Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo.

Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ, Witte MD, van der Linden WA, van den Nieuwendijk AM, Hofmann T, Berkers CR, van Leeuwen FW, Groothuis TA, Leeuwenburgh MA, Ovaa H, Neefjes JJ, Filippov DV, van der Marel GA, Dantuma NP, Overkleeft HS.

Chem Biol. 2006 Nov;13(11):1217-26.

2.

Profiling proteasome activity in tissue with fluorescent probes.

Berkers CR, van Leeuwen FW, Groothuis TA, Peperzak V, van Tilburg EW, Borst J, Neefjes JJ, Ovaa H.

Mol Pharm. 2007 Sep-Oct;4(5):739-48. Epub 2007 Aug 21.

PMID:
17708652
3.

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.

Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK.

Blood. 2009 Oct 15;114(16):3439-47. doi: 10.1182/blood-2009-05-223677. Epub 2009 Aug 11.

4.

Proteasome activity profiling: a simple, robust and versatile method revealing subunit-selective inhibitors and cytoplasmic, defense-induced proteasome activities.

Gu C, Kolodziejek I, Misas-Villamil J, Shindo T, Colby T, Verdoes M, Richau KH, Schmidt J, Overkleeft HS, van der Hoorn RA.

Plant J. 2010 Apr 1;62(1):160-70. doi: 10.1111/j.1365-313X.2009.04122.x. Epub 2009 Dec 23.

6.

Synthesis and biological evaluation of new vinyl ester pseudotripeptide proteasome inhibitors.

Marastoni M, Baldisserotto A, Trapella C, Gavioli R, Tomatis R.

Eur J Med Chem. 2006 Aug;41(8):978-84. Epub 2006 May 18.

PMID:
16713026
7.

Fluorescence-based proteasome activity profiling.

de Jong A, Schuurman KG, Rodenko B, Ovaa H, Berkers CR.

Methods Mol Biol. 2012;803:183-204. doi: 10.1007/978-1-61779-364-6_13.

PMID:
22065226
8.

Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.

Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D, Takahashi Y, Akamatsu Y.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2343-5. doi: 10.1016/j.bmcl.2009.02.117. Epub 2009 Mar 4.

PMID:
19307118
9.

O-GlcNAc peptide epoxyketones are recognized by mammalian proteasomes.

Witte MD, Florea BI, Verdoes M, Adeyanju O, Van der Marel GA, Overkleeft HS.

J Am Chem Soc. 2009 Sep 2;131(34):12064-5. doi: 10.1021/ja901231w.

PMID:
19658393
10.

Synthesis and proteasome inhibition of N-allyl vinyl ester-based peptides.

Baldisserotto A, Franceschini C, Scalambra F, Trapella C, Marastoni M, Sforza F, Gavioli R, Tomatis R.

J Pept Sci. 2010 Nov;16(11):659-63. doi: 10.1002/psc.1280.

PMID:
20814885
11.

Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.

Zhu Y, Yao S, Xu B, Ge Z, Cui J, Cheng T, Li R.

Bioorg Med Chem. 2009 Oct 1;17(19):6851-61. doi: 10.1016/j.bmc.2009.08.023. Epub 2009 Aug 20.

PMID:
19747832
12.

Monitoring the distribution and dynamics of proteasomes in living cells.

Groothuis TA, Reits EA.

Methods Enzymol. 2005;399:549-63.

PMID:
16338381
13.

Small-molecule inhibitors of proteasome activity.

Gaczynska M, Osmulski PA.

Methods Mol Biol. 2005;301:3-22. Review.

PMID:
15917622
14.

Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy.

Chen CS, Chen WN, Zhou M, Arttamangkul S, Haugland RP.

J Biochem Biophys Methods. 2000 Mar 16;42(3):137-51.

PMID:
10737220
15.

Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines.

Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, Drung I, Kloetzel PM, Schmidt B.

J Biol Chem. 2005 Aug 5;280(31):28394-401. Epub 2005 May 26.

16.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J.

J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v.

PMID:
19348473
17.

Proteasome selectivity towards Michael acceptor containing oligopeptide-based inhibitors.

van der Linden WA, Geurink PP, Oskam C, van der Marel GA, Florea BI, Overkleeft HS.

Org Biomol Chem. 2010 Apr 21;8(8):1885-93. doi: 10.1039/b924134e.

PMID:
20449494
18.

A new fluorogenic peptide determines proteasome activity in single cells.

Urru SA, Veglianese P, De Luigi A, Fumagalli E, Erba E, Gonella Diaza R, CarrĂ  A, Davoli E, Borsello T, Forloni G, Pengo N, Monzani E, Cascio P, Cenci S, Sitia R, Salmona M.

J Med Chem. 2010 Oct 28;53(20):7452-60. doi: 10.1021/jm100362x.

PMID:
20883027
19.

Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors.

Watanabe T, Abe H, Momose I, Takahashi Y, Ikeda D, Akamatsu Y.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5839-42. doi: 10.1016/j.bmcl.2010.07.122. Epub 2010 Aug 1.

PMID:
20727746
20.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

Supplemental Content

Support Center